Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017405
Filing Date
2022-11-10
Accepted
2022-11-10 16:05:58
Documents
67
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rain-20220930x10q.htm   iXBRL 10-Q 1729906
2 EX-31.1 rain-20220930xex31d1.htm EX-31.1 12841
3 EX-31.2 rain-20220930xex31d2.htm EX-31.2 16743
4 EX-32.1 rain-20220930xex32d1.htm EX-32.1 12817
5 GRAPHIC rain-20220930x10q006.jpg GRAPHIC 52289
  Complete submission text file 0001558370-22-017405.txt   7626078

Data Files

Seq Description Document Type Size
6 EX-101.SCH rain-20220930.xsd EX-101.SCH 56838
7 EX-101.CAL rain-20220930_cal.xml EX-101.CAL 50463
8 EX-101.DEF rain-20220930_def.xml EX-101.DEF 205695
9 EX-101.LAB rain-20220930_lab.xml EX-101.LAB 514518
10 EX-101.PRE rain-20220930_pre.xml EX-101.PRE 364737
61 EXTRACTED XBRL INSTANCE DOCUMENT rain-20220930x10q_htm.xml XML 1361443
Mailing Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560
Business Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560 (510) 953-5559
Rain Therapeutics Inc. (Filer) CIK: 0001724979 (see all company filings)

EIN.: 821130967 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40356 | Film No.: 221377044
SIC: 2834 Pharmaceutical Preparations